Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Joint Venture Agreement

8 Jun 2007 07:01

Ovoca Gold PLC08 June 2007 Ovoca Gold plc ("Ovoca Gold" or the "Company") Ovoca Gold Joint Venture Agreement with BKG Exploration on the Klippen Gold Project in Sweden Ovoca Gold Plc (AIM: OVG; IEX: OVX) is pleased to announce a Joint VentureAgreement with BKG Exploration Limited ("BKG") to explore the Swedish licenceareas held by Ovoca's subsidiary, Klippen Guld AB ("Klippen"), which number atotal of 13 licences and cover an area of 25,387 hectares. The agreement allows BKG to earn a 50% interest in Klippen in return for meetingthe operational and management expenses of the company and carrying out anexploration programme which includes drilling a minimum of 2,000 meters, withineighteen months. BKG will also meet all the licence renewal, tax andexploration obligations during that period. On completion of the drillingprogramme, BKG will have an option to purchase the balance of Ovoca's shares inKlippen in return for meeting all the ongoing exploration, development andmanagement costs of Klippen and providing Ovoca with a 1.5% Net Smelter Return. Leonid Skoptsov, CEO of Ovoca, commented "Klippen is an exciting greenfieldsexploration project. With Ovoca currently focussing manpower and funding ondeveloping the Goltsovoye silver deposit in Russia, we are happy to partner withBKG, whose wealth of experience and success in the mineral industry will provideKlippen with the momentum to continue its development. " Ovoca acquired Klippen from Minmet plc in 2003 and has been exploring in theVasterbotten "Gold Line" district since then. BKG Exploration is a private exploration company established to acquire mineraland petroleum exploration projects in Scandinavia, Africa and Mongolia. Ovoca Gold Plc is an international exploration company quoted in London (OVG.L) and Dublin (OVX.IR), exploring for precious and base metals in Russia, Sweden and Ireland For further information please visit www.ovocagold.com or contact: Simon Beardsmore, Commercial Manager - Ovoca John O'Connor, CFO - Ovoca Gold PlcGold Plc Tel: +44 (0)207 397 8152Tel: +44 (0)207 397 8159 Email: john.oconnor@ovocagold.comEmail: simon.beardsmore@ovocagold.com John Frain - Davy Nick Bias / Alex Buck - BuckBias (UK PR) Tel: +353 (0)1 679 6363 Tel: +44 (0)7887 920 530 / +44 (0)7932 740 452 Email: john.frain@davy.ie Email: nick@buckbias.com / alex@buckbias.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Feb 20267:00 amRNSChange of Name
28th Jan 20268:00 amRNSReadmission - Ovoca Bio PLC
28th Jan 20267:00 amRNSFirst Day of Dealings on AIM
27th Jan 20262:32 pmRNSResult of Meeting
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20257:00 amRNSNotice of AGM
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSNotice of AGM
13th Nov 20257:00 amRNSChange of Broker
30th Sep 20251:09 pmRNSReplacement Half Year Report
30th Sep 20257:00 amRNSHalf-year Report
26th Jun 20257:00 amRNSPublication of 2024 Annual Report
5th Jun 20257:00 amRNSDelisting from Euronext Growth Exchange
7th May 20257:30 amRNSSuspension - Ovoca Bio plc
7th May 20257:00 amRNSProposed Acquisition, Disposal & Reverse Takeover
3rd Mar 20252:00 pmRNSManagement Changes
18th Dec 20246:00 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM
11th Oct 20245:30 pmRNSHolding(s) in Company
9th Oct 20245:45 pmRNSSale of Treasury Shares
25th Sep 20247:00 amRNSHalf-year Report
2nd Sep 20242:30 pmRNSConsultancy Agreement
15th Jul 20247:00 amRNSDirector/PDMR Shareholding
15th Jul 20247:00 amRNSDirectorate Change
28th Jun 20247:00 amRNSAnnual Financial Report
23rd Jan 20247:00 amRNSHolding(s) in Company
1st Dec 202312:00 pmRNSResult of AGM
7th Nov 20239:15 amRNSNotice of AGM
28th Sep 20237:00 amRNSInterim Results
31st Aug 20237:00 amRNSSummary Results of Phase II Study for Orenetide
30th Jun 20237:00 amRNSAnnual Financial Report
12th Jun 20237:00 amRNSUpdate on Completion Timelines for Phase II Study
16th Mar 20234:35 pmRNSPrice Monitoring Extension
16th Mar 20232:05 pmRNSSecond Price Monitoring Extn
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 20239:05 amRNSSecond Price Monitoring Extn
16th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20237:00 amRNSDisposal of Russian Assets
14th Feb 20234:41 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20232:05 pmRNSSecond Price Monitoring Extn
14th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSResult of AGM
6th Oct 20222:30 pmRNSNotice of AGM
30th Sep 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.